{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:05:09Z","timestamp":1776341109318,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"crossref","award":["14055"],"award-info":[{"award-number":["14055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate whether breast radiologic response on breast MRI can predict axillary pathologic response (ypN0 vs. ypN+) in breast cancer patients treated with neoadjuvant chemotherapy (NACT) in the total study population and in subgroups according to clinical nodal (cN)-status and oestrogen receptor (ER)-expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective single-centre study consecutively included breast cancer patients who, between 2012 and 2022, had undergone baseline and post-NACT breast MRI. Measures of predictive ability, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic odds ratio (DOR) with 95% confidence intervals (CI), were calculated. Subgroup analyses were performed for cN-status and ER expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 251 included patients, 48.6% were cN0 and 34.7% had ER-negative tumours. For axillary pathologic response prediction by breast MRI, the sensitivity was 84%, specificity 40.4%, PPV 48.3%, NPV 79.2%, and DOR 3.6 (95% CI: 1.83\u20137.00). The probability of achieving ypN0 was 60.2% in all patients, 82% in cN0 patients versus 39.5% in cN+ patients, and 78.2% in ER-negative tumours versus 50.6% in ER-positive tumours. High NPVs were observed in cN0 patients (92%) and ER-negative tumours (90.1%) and were lower in cN+ patients (62.2%) and ER-positive tumours (72.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The probability of ypN+ given breast complete response on breast MRI was below 10% in cN0 patients and ER-negative tumours. Therefore, in these subgroups, breast complete response on breast MRI may be clinically useful to exclude ypN+. In cN+ patients and ER-positive tumours, due to lower NPVs, breast complete response on breast MRI may not be clinically useful to exclude ypN+.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Accurate non-invasive methods to differentiate between patients with and without axillary pathologic complete response after neoadjuvant chemotherapy prior to axillary surgery are currently lacking<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Breast complete response on MRI after neoadjuvant chemotherapy indicates a low probability (&lt;\u200910%) of axillary residual disease in clinically node-negative patients and oestrogen receptor-negative tumours<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Breast complete response on MRI may be a non-invasive, clinically useful tool to exclude patients with axillary residual disease after neoadjuvant chemotherapy prior to axillary surgery and guide patient selection for potential de-escalation of axillary treatment<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-12249-x","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:11:18Z","timestamp":1766506278000},"page":"3358-3366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9874-8007","authenticated-orcid":false,"given":"Florien J. G.","family":"van Amstel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik G. M.","family":"van Mierlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patty J.","family":"Nelemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne M. E.","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janneke","family":"Houwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loes F. S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivianne C. G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiemo J. A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"12249_CR1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194\u20131220","journal-title":"Ann Oncol"},{"key":"12249_CR2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485\u20131505","journal-title":"J Clin Oncol"},{"key":"12249_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00330-017-5121-4","volume":"28","author":"P Clauser","year":"2018","unstructured":"Clauser P, Mann R, Athanasiou A et al (2018) A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice. Eur Radiol 28:1909\u20131918","journal-title":"Eur Radiol"},{"key":"12249_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"M Lobbes","year":"2013","unstructured":"Lobbes M, Prevos R, Smidt M et al (2013) The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 4:163\u2013175","journal-title":"Insights Imaging"},{"key":"12249_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejso.2020.08.023","volume":"47","author":"J Woo","year":"2021","unstructured":"Woo J, Ryu JM, Jung SM et al (2021) Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 47:232\u2013239","journal-title":"Eur J Surg Oncol"},{"key":"12249_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-016-0742-0","volume":"18","author":"CE Loo","year":"2016","unstructured":"Loo CE, Rigter LS, Pengel KE et al (2016) Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Res 18:1\u201312","journal-title":"Breast Cancer Res"},{"key":"12249_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-018-1091-y","volume":"21","author":"SP Gampenrieder","year":"2019","unstructured":"Gampenrieder SP, Peer A, Weismann C et al (2019) Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res 21:1\u201311","journal-title":"Breast Cancer Res"},{"key":"12249_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","volume":"273","author":"S Samiei","year":"2021","unstructured":"Samiei S, de Mooij CM, Lobbes MB, Keymeulen KB, van Nijnatten TJ, Smidt ML (2021) Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 273:694\u2013700","journal-title":"Ann Surg"},{"key":"12249_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.crad.2017.09.005","volume":"73","author":"TJA van Nijnatten","year":"2018","unstructured":"van Nijnatten TJA, Schipper RJ, Lobbes MBI et al (2018) Diagnostic performance of gadofosveset-enhanced axillary MRI for nodal (re)staging in breast cancer patients: results of a validation study. Clin Radiol 73:168\u2013175","journal-title":"Clin Radiol"},{"key":"12249_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1148\/radiol.2021202683","volume":"300","author":"JH Byon","year":"2021","unstructured":"Byon JH, Park YV, Yoon JH et al (2021) Added value of MRI for invasive breast cancer including the entire axilla for evaluation of high-level or advanced axillary lymph node metastasis in the post-ACOSOG Z0011 trial era. Radiology 300:46\u201354","journal-title":"Radiology"},{"key":"12249_CR11","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SM et al (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156:e210891","journal-title":"JAMA Surg"},{"key":"12249_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"Samiei S, van Nijnatten TJ, de Munck L et al (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271:574\u2013580","journal-title":"Ann Surg"},{"key":"12249_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152:665\u2013670","journal-title":"JAMA Surg"},{"key":"12249_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.21037\/atm-20-5172","volume":"8","author":"J Zhu","year":"2020","unstructured":"Zhu J, Li J, Fan Z et al (2020) Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy. Ann Transl Med 8:992","journal-title":"Ann Transl Med"},{"key":"12249_CR15","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1245\/s10434-021-10519-8","volume":"28","author":"DW Lim","year":"2021","unstructured":"Lim DW, Greene BD, Look Hong NJ (2021) Relationship between breast and axillary pathologic complete response in women receiving neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 28:5495\u20135506","journal-title":"Ann Surg Oncol"},{"key":"12249_CR16","doi-asserted-by":"crossref","unstructured":"de Wild SR, Koppert LB, de Munck L et al (2023) Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study. Breast Cancer Res Treat 204:277\u2013288","DOI":"10.1007\/s10549-023-07178-6"},{"key":"12249_CR17","doi-asserted-by":"crossref","unstructured":"Chotai N, Kulkarni S (2020) BI-RADS Lexicon. In Breast Imaging Essentials: Case Based Review (pp. 37\u201338). Singapore: Springer Singapore.","DOI":"10.1007\/978-981-15-1412-8_8"},{"key":"12249_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122","journal-title":"J Clin Oncol"},{"key":"12249_CR19","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997\u20134013","journal-title":"J Clin Oncol"},{"key":"12249_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"12249_CR21","unstructured":"NABON (2023) National breast cancer guideline, Oncoline. Available via https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/behandeling_invasief_carcinoom\/neoadjuvante_behandeling\/systemische_therapie.html. Accessed 20 Dec 2024"},{"key":"12249_CR22","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/ijms24032969","volume":"24","author":"NS van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CH (2023) Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci 24:2969","journal-title":"Int J Mol Sci"},{"key":"12249_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, van Nijnatten TJ, van der Pol CC, Luiten EJ, Koppert LB, Smidt ML (2019) Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 269:432","journal-title":"Ann Surg"},{"key":"12249_CR24","unstructured":"ClinicalTrials.gov (2020) Avoiding sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy (ASICS). Available via https:\/\/clinicaltrials.gov\/study\/NCT04225858. Accessed 29 Oct 2025"},{"key":"12249_CR25","unstructured":"ClinicalTrials.gov (2025) No axillary surgical treatment in clinically lymph node negative patients on ultrasonography after neoadjuvant chemotherapy (Neo-NAUTILUS). Available via https:\/\/clinicaltrials.gov\/study\/NCT06704945. Accessed 29 Oct 2025"},{"key":"12249_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","volume":"180","author":"JM Simons","year":"2020","unstructured":"Simons JM, Koppert LB, Luiten E et al (2020) De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Res Treat 180:725\u2013733","journal-title":"Breast Cancer Res Treat"},{"key":"12249_CR27","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.clbc.2021.07.011","volume":"22","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, Simons JM, Peeters M-JTV, Smidt ML, Koppert LB, Group M (2022) MINImal vs. MAXimal invasive axillary staging and treatment after neoadjuvant systemic therapy in node positive breast cancer: protocol of a Dutch Multicenter Registry Study (MINIMAX). Clin Breast Cancer 22:e59\u2013e64","journal-title":"Clin Breast Cancer"},{"key":"12249_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","volume":"193","author":"AA van Loevezijn","year":"2022","unstructured":"van Loevezijn AA, van der Noordaa ME, Stokkel MP et al (2022) Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol. Breast Cancer Res Treat 193:37\u201348","journal-title":"Breast Cancer Res Treat"},{"key":"12249_CR29","first-page":"117822342211035","volume":"16","author":"R Browne","year":"2022","unstructured":"Browne R, McAnena P, O\u2019Halloran N et al (2022) Preoperative breast magnetic resonance imaging as a predictor of response to neoadjuvant chemotherapy. Breast Cancer 16:11782234221103504","journal-title":"Breast Cancer"},{"key":"12249_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00475-1","volume":"8","author":"L Janssen","year":"2022","unstructured":"Janssen L, Den Dekker B, Gilhuijs K, Van Diest P, Van Der Wall E, Elias S (2022) MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis. NPJ Breast Cancer 8:107","journal-title":"NPJ Breast Cancer"},{"key":"12249_CR31","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1007\/s00330-021-08461-0","volume":"32","author":"J Kim","year":"2022","unstructured":"Kim J, Han B-K, Ko EY, Ko ES, Choi JS, Park KW (2022) Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes. Eur Radiol 32:4056\u20134066","journal-title":"Eur Radiol"},{"key":"12249_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.108701","volume":"120","author":"EM Negr\u00e3o","year":"2019","unstructured":"Negr\u00e3o EM, Souza JA, Marques EF, Bitencourt AG (2019) Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol 120:108701","journal-title":"Eur J Radiol"},{"key":"12249_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1067\/j.cpradiol.2019.07.003","volume":"49","author":"VS \u00d6zt\u00fcrk","year":"2020","unstructured":"\u00d6zt\u00fcrk VS, Polat YD, Soyder A, Tanyeri A, Karaman CZ, Ta\u015fk\u0131n F (2020) The relationship between MRI findings and molecular subtypes in women with breast cancer. Curr Probl Diagn Radiol 49:417\u2013421","journal-title":"Curr Probl Diagn Radiol"},{"key":"12249_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-022-00289-7","volume":"6","author":"F Galati","year":"2022","unstructured":"Galati F, Rizzo V, Moffa G et al (2022) Radiologic-pathologic correlation in breast cancer: do MRI biomarkers correlate with pathologic features and molecular subtypes? Eur Radiol Exp 6:39","journal-title":"Eur Radiol Exp"},{"key":"12249_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","volume":"29","author":"CE Loo","year":"2011","unstructured":"Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660\u2013666","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s00330-026-12508-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000}}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12249-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:22:39Z","timestamp":1776338559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12249-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["12249"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12249-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The continuation of Table 3 starts with incorrect sub-heading \u201ccN0\u201d. The correct sub-heading is \u201cER-positive\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00330-026-12508-5","URL":"https:\/\/doi.org\/10.1007\/s00330-026-12508-5","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Thiemo J.A. van Nijnatten, Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Prof. Dr. Marjolein L. Smidt received institutional research funding not related to this study from Servier, Pharma, Nutricia and Illumina for the microbiota study. Dr. Thiemo J.A. van Nijnatten received speaker honoraria and institutional grant support and reports participation in medical advisory board meetings for Bayer and GE Healthcare, not related to the content of this study. Dr. Thiemo J.A. van Nijnatten reports participation in medical advisory board meetings for Screenpoint Medical, not related to the content of this study. Dr. Loes F.S. Kooreman received institutional honoraria for education and national guideline advisory. Prof. Dr. Vivianne C.G. Tjan-Heijnen received institutional research funding outside this work, from Novartis, E Lilly, Daiichi Sankyo, AstraZeneca and Gilead, and received honoraria from Novartis and E Lilly. Prof. Dr. Sabine Siesling is a member of the advisory board of Evidencio and Vivica, not related to this study. The other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (P.J. Nelemans) has significant statistical expertise. No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained by the Medical Ethics Review Committee azM\/UM (reference number: 2022-3481) of Maastricht University Medical Centre+, Maastricht, the Netherlands.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}